MEDICAL CROSSFIRE®: Progressive Fibrosis-Interstitial Lung Disease (PF-ILD): Navigating the Complex Pathways to Diagnosis, Management, and Emerging Therapies

Released On
June 30, 2019

Expires On
June 30, 2020

Media Type
Internet

Completion Time
90 minutes

Specialty
Pulmonology, Pathology

Topic(s)
Interstitial Lung Disease

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians' Education Resource®, LLC.

 

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — maximum of 1.5 contact hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward pulmonologists, rheumatologists, radiologists, clinical immunologists, allergists, specialty nurse practitioners, physician assistants, primary care clinicians and other healthcare professionals involved in the treatment of patients with PF-ILD.

Program Overview

Interstitial lung diseases (ILDs) are a diffuse group of over 200 lung disorders which are associated with substantial morbidity and mortality. Most of them are rare but when pulmonary fibrosis predominates, they are particularly difficult to treat and manage and patients bear a severely diminished quality of life. Idiopathic pulmonary fibrosis is considered the classic presentation of the fibrotic interstitial lung diseases but other ILD etiologies exhibit similarities with the presence of worsening pulmonary fibrosis and respiratory symptoms, declining lung function, and resistance to immunomodulatory treatments related to other diseases such as rheumatoid arthritis and systemic sclerosis or to environmental exposures and unknown causes.

Early diagnosis and disease intervention are critical for these patients, but lengthy delays and misdiagnoses are common. Typical presenting symptoms are more likely to be an indication of a common respiratory or cardiovascular condition and clinicians will rule out those diagnoses by exposing patients to costly and invasive testing with limited consideration for the possibility of a rare interstitial lung disease. Diagnosis of ILDs is complex and involves careful exclusion of alternative etiologies by a multidisciplinary team integrating findings from clinical, radiologic, and pathologic exam. During this Medical Crossfire®, expert faculty specializing in pulmonology, rheumatology and diagnostic radiology will share their clinical practice insights for making an accurate diagnosis and considering treatment with antifibrotics that can delay disease progression. Faculty will then elaborate on strategies for clinician-patient collaboration to individualize a comprehensive treatment program that addresses comorbidities, patient expectations and best possible quality of life.

Benefits of Participating

  • Gain familiarity with etiologies and early recognizable signs and symptoms of interstitial lung diseases
  • Learn the role of antifibrotics in disease management and how to set patient treatment expectations
  • Understand the benefits of a multidisciplinary approach to diagnosis and ongoing disease management

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify key mechanisms underlying the varied forms of PF-ILD, clinical presentation and management.
  • Assess the pathological patterns of fibrosis in PF-ILD and their role in defining disease etiology and subsequent management.
  • Examine the role of current and emerging agents in the treatment of patients with PF-ILDs.
  • Implement team-based strategies to improve individualization of treatment plans for patients with PF-ILD.

Chair

Steven Nathan, MD

Medical Director, Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Professor of Medicine, Virginia Commonwealth University

Faculty

Monique Hinchcliff, MD, MS

Associate Professor of Medicine
Director of Clinical Research
Director of Yale Scleroderma Program
New Haven, Connecticut

Ami N. Rubinowitz, MD

Associate Professor Thoracic Imaging Section
Department of Radiology and Biomedical Imaging
Yale University School of Medicine, Yale-New Haven Hospital
New Haven, CT

Joshua J. Solomon, MD

Associate Chief, Section of Critical Care
Associate Professor
Department of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Health
Denver, CO

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians and is a provider approved by the California Board of Registered Nursing (CBRN).

Physicians Credit Designation Statement

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™ and for 1.5 contact hours for nurses. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation Statement

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Disclosures of Conflicts of Interest

The following contributors have relevant financial relationships with commercial interests to disclose:

Steven Nathan, MD

  • Grant Research Support: Biogen
  • Consultant: Roche-Genentech, Boerhinger-Ingelheim, Galapagos, Promedior, Bellerophon, United Therapeutics
  • Speakers Bureau: Roche-Genentech, Boerhinger-Ingelheim.

Monique Hinchcliff, MD, MS

  • No relevant financial relationships with commercial interests to disclose.

Ami N. Rubinowitz, MD

  • No relevant financial relationships with commercial interests to disclose.

Joshua J. Solomon, MD

  • Grant Research Support: Pfizer, Boehringer Ingelheim; Speakers Bureau: Genentech.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclosure of Unlabeled Use

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

 

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process